CA2858963C - Vaccines against hpv - Google Patents

Vaccines against hpv Download PDF

Info

Publication number
CA2858963C
CA2858963C CA2858963A CA2858963A CA2858963C CA 2858963 C CA2858963 C CA 2858963C CA 2858963 A CA2858963 A CA 2858963A CA 2858963 A CA2858963 A CA 2858963A CA 2858963 C CA2858963 C CA 2858963C
Authority
CA
Canada
Prior art keywords
seq
amino acid
sequence
homodimeric protein
protein according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2858963A
Other languages
English (en)
French (fr)
Other versions
CA2858963A1 (en
Inventor
Ole Henrik Brekke
Agnete Brunsvik Fredriksen
Ali AREFFARD
Mona Mari LINDEBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nykode Therapeutics ASA
Original Assignee
Nykode Therapeutics ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nykode Therapeutics ASA filed Critical Nykode Therapeutics ASA
Publication of CA2858963A1 publication Critical patent/CA2858963A1/en
Application granted granted Critical
Publication of CA2858963C publication Critical patent/CA2858963C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2858963A 2011-12-21 2012-12-20 Vaccines against hpv Active CA2858963C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578542P 2011-12-21 2011-12-21
US61/578,542 2011-12-21
PCT/EP2012/076404 WO2013092875A1 (en) 2011-12-21 2012-12-20 Vaccines against hpv

Publications (2)

Publication Number Publication Date
CA2858963A1 CA2858963A1 (en) 2013-06-27
CA2858963C true CA2858963C (en) 2023-05-23

Family

ID=47471832

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2858963A Active CA2858963C (en) 2011-12-21 2012-12-20 Vaccines against hpv

Country Status (17)

Country Link
US (1) US9901635B2 (enExample)
EP (2) EP3533462A1 (enExample)
JP (1) JP6258864B2 (enExample)
KR (1) KR102057265B1 (enExample)
CN (1) CN104039833B (enExample)
AU (1) AU2012356969B2 (enExample)
BR (1) BR112014015016B1 (enExample)
CA (1) CA2858963C (enExample)
DK (1) DK2793937T3 (enExample)
ES (1) ES2730718T3 (enExample)
HU (1) HUE043361T2 (enExample)
IL (1) IL233217B (enExample)
PT (1) PT2793937T (enExample)
RU (1) RU2644201C2 (enExample)
TR (1) TR201908199T4 (enExample)
WO (1) WO2013092875A1 (enExample)
ZA (1) ZA201404516B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970466A1 (en) * 2013-03-15 2016-01-20 Vaccibody AS Targeting vaccines for veterinary use
CN106103483A (zh) 2014-01-13 2016-11-09 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
KR102523984B1 (ko) * 2014-08-15 2023-04-20 주식회사 제넥신 자궁경부 종양의 치료 방법
CA2995740A1 (en) * 2015-08-20 2017-02-23 Janssen Vaccines & Prevention B.V. Therapeutic hpv18 vaccines
AU2017205270B2 (en) * 2016-01-08 2024-01-18 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
WO2019048936A1 (en) * 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
WO2019048928A1 (en) * 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
US20230293650A1 (en) 2020-04-09 2023-09-21 Nykode Therapeutics ASA Individualized therapeutic anticancer vaccine
US11883479B2 (en) 2020-04-24 2024-01-30 Genexine, Inc. Method for treating cervical cancer
CN116096735A (zh) 2020-05-01 2023-05-09 耐考德治疗股份有限公司 乙型冠状病毒的预防和治疗
KR20230164118A (ko) 2021-03-26 2023-12-01 니코데 테라퓨틱스 에이에스에이 암 치료를 위한 치료 조합
US20250339509A1 (en) 2021-05-03 2025-11-06 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
WO2022238363A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
EP4337247A1 (en) 2021-05-10 2024-03-20 Nykode Therapeutics ASA Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders
JP2024518463A (ja) 2021-05-10 2024-05-01 ナイコード セラピューティクス アルメン アクスイェ セルスカプ 構築物及び免疫阻害化合物の共発現
EP4337251A1 (en) 2021-05-10 2024-03-20 Nykode Therapeutics ASA Tolerance-inducing constructs and composition and their use for the treatment of immune disorders
WO2022238420A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Co-expression of constructs and immunostimulatory compounds
WO2023079001A1 (en) 2021-11-03 2023-05-11 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
EP4615980A1 (en) 2022-11-09 2025-09-17 Nykode Therapeutics ASA Co-expression of constructs and polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
PT1553966E (pt) * 2002-10-03 2012-10-22 Wyeth Corp Péptidos de fusão que compreendem os polipéptidos e7 e e6 do vírus do papiloma humano e as composições imunogénicas dos mesmos
EP2862878B1 (en) 2003-02-25 2022-11-02 Nykode Therapeutics ASA Modified antibody
EP1576967B1 (en) * 2004-03-18 2007-09-12 Institut Pasteur Recombinant protein, carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof, therapeutic uses thereof
EP1846026A4 (en) 2005-01-26 2008-07-02 Univ Johns Hopkins ANTIBODY DNA VACCINE WITH PLASMIDES FOR CODING A MUTATED ONCOPROTEIN ANTIGEN AND CALRETICULIN
DK2585107T3 (en) * 2010-06-25 2019-02-11 Vaccibody As Homodimeric protein constructs

Also Published As

Publication number Publication date
US9901635B2 (en) 2018-02-27
US20150056197A1 (en) 2015-02-26
ZA201404516B (en) 2017-04-26
TR201908199T4 (tr) 2019-06-21
JP2015508284A (ja) 2015-03-19
CN104039833A (zh) 2014-09-10
KR20140107569A (ko) 2014-09-04
CA2858963A1 (en) 2013-06-27
NZ626124A (en) 2016-07-29
PT2793937T (pt) 2019-06-05
US20150306217A9 (en) 2015-10-29
HK1202442A1 (en) 2015-10-02
BR112014015016A2 (pt) 2020-10-27
EP3533462A1 (en) 2019-09-04
DK2793937T3 (da) 2019-07-01
JP6258864B2 (ja) 2018-01-10
BR112014015016A8 (pt) 2023-05-09
ES2730718T3 (es) 2019-11-12
IL233217B (en) 2019-05-30
HUE043361T2 (hu) 2019-08-28
AU2012356969B2 (en) 2017-05-04
WO2013092875A1 (en) 2013-06-27
EP2793937A1 (en) 2014-10-29
RU2644201C2 (ru) 2018-02-08
BR112014015016B1 (pt) 2023-10-03
RU2014129788A (ru) 2016-02-10
CN104039833B (zh) 2018-01-30
EP2793937B1 (en) 2019-04-10
KR102057265B1 (ko) 2019-12-18
IL233217A0 (en) 2014-08-31
AU2012356969A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
CA2858963C (en) Vaccines against hpv
US20200239568A1 (en) Homodimeric protein constructs
TW200844230A (en) Signaling peptides
US20140234316A1 (en) Vaccibodies targeted to cross-presenting dendritic cells
HK1202442B (en) Vaccines against hpv
NZ626124B2 (en) Vaccines against hpv

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171121

EEER Examination request

Effective date: 20171121

EEER Examination request

Effective date: 20171121

EEER Examination request

Effective date: 20171121

EEER Examination request

Effective date: 20171121

EEER Examination request

Effective date: 20171121